Read More Pharma Industry News Why Shilpa’s bet on Alveolus Bio may reshape the future of pulmonary biologics Shilpa Medicare leads funding round in Alveolus Bio to accelerate Phase 2 COPD trials and first-in-human studies for novel inhaled therapeutics. byPallavi MadhirajuAugust 4, 2025